Cryopreserved or Fresh Mesenchymal Stromal Cells: Only a Matter of Taste or Key to Unleash the Full Clinical Potential of MSC Therapy?
暂无分享,去创建一个
D. Strunk | S. Geissler | O. Ringdén | M. Hoogduijn | K. Bieback | Guido Moll | L. Ignatowicz | R. Catar
[1] G. Lucchini,et al. Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey , 2016, Haematologica.
[2] D. Stewart,et al. Brief Report: Elastin Microfibril Interface 1 and Integrin‐Linked Protein Kinase Are Novel Markers of Islet Regenerative Function in Human Multipotent Mesenchymal Stromal Cells , 2016, Stem cells.
[3] A. Kirk,et al. Cryopreserved Mesenchymal Stromal Cells Are Susceptible to T‐Cell Mediated Apoptosis Which Is Partly Rescued by IFNγ Licensing , 2016, Stem cells.
[4] P. Saas,et al. Concise Review: Apoptotic Cell‐Based Therapies–Rationale, Preclinical Results and Future Clinical Developments , 2016, Stem cells.
[5] M. Janowski,et al. Extracellular Vesicles in Physiology, Pathology, and Therapy of the Immune and Central Nervous System, with Focus on Extracellular Vesicles Derived from Mesenchymal Stem Cells as Therapeutic Tools , 2016, Front. Cell. Neurosci..
[6] U. Galderisi,et al. Clinical Trials with Mesenchymal Stem Cells: An Update , 2016, Cell transplantation.
[7] A. Morelli,et al. Concise Review: Mechanisms Behind Apoptotic Cell‐Based Therapies Against Transplant Rejection and Graft versus Host Disease , 2016, Stem cells.
[8] W. Fibbe,et al. Unraveling mechanisms of mesenchymal stromal cell–mediated immunomodulation through patient monitoring and product characterization , 2016, Annals of the New York Academy of Sciences.
[9] Michael S. Roberts,et al. A physiologically based kinetic model for elucidating the in vivo distribution of administered mesenchymal stem cells , 2016, Scientific Reports.
[10] J. Boltze,et al. Clumping and Viability of Bone Marrow Derived Mesenchymal Stromal Cells under Different Preparation Procedures: A Flow Cytometry-Based In Vitro Study , 2016, Stem cells international.
[11] W. V. van IJcken,et al. Effects of Freeze-Thawing and Intravenous Infusion on Mesenchymal Stromal Cell Gene Expression. , 2016, Stem cells and development.
[12] F. Chédin,et al. Comprehensive Proteomic Analysis of Mesenchymal Stem Cell Exosomes Reveals Modulation of Angiogenesis via Nuclear Factor‐KappaB Signaling , 2016, Stem cells.
[13] J. Krasko,et al. Identity, proliferation capacity, genomic stability and novel senescence markers of mesenchymal stem cells isolated from low volume of human bone marrow , 2016, Oncotarget.
[14] C. Aguayo,et al. Mesenchymal Stem Cell-Derived Extracellular Vesicles Promote Angiogenesis: Potencial Clinical Application , 2016, Front. Physiol..
[15] S. Ferguson,et al. An in vitro expansion score for tissue‐engineering applications with human bone marrow‐derived mesenchymal stem cells , 2016, Journal of tissue engineering and regenerative medicine.
[16] U. Platzbecker,et al. Mesenchymal Stromal Cells for Treatment of Acute Steroid‐Refractory Graft Versus Host Disease: Clinical Responses and Long‐Term Outcome , 2016, Stem cells.
[17] Ivan Martin,et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. , 2016, Cytotherapy.
[18] B. Giebel,et al. Mesenchymal stem/stromal cell‐derived extracellular vesicles as a new approach in stem cell therapy , 2016 .
[19] M. Murad,et al. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. , 2016, The Lancet. Haematology.
[20] R. Henschler,et al. Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells , 2016, Stem Cell Research & Therapy.
[21] A. Reinisch,et al. A robust potency assay highlights significant donor variation of human mesenchymal stem/progenitor cell immune modulatory capacity and extended radio-resistance , 2015, Stem Cell Research & Therapy.
[22] Simon C Watkins,et al. Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs , 2015, Nature Communications.
[23] Locksley E McGann,et al. Mesenchymal stromal cells derived from various tissues: Biological, clinical and cryopreservation aspects. , 2015, Cryobiology.
[24] F. Barry,et al. Bone Marrow‐Derived Mesenchymal Stem Cells Have Innate Procoagulant Activity and Cause Microvascular Obstruction Following Intracoronary Delivery: Amelioration by Antithrombin Therapy , 2015, Stem cells.
[25] Xufeng,et al. Cryopreservation of Human Mesenchymal Stem Cells for Clinical Applications: Current Methods and Challenges , 2015 .
[26] A. Schmidtchen,et al. Different Procoagulant Activity of Therapeutic Mesenchymal Stromal Cells Derived from Bone Marrow and Placental Decidua. , 2015, Stem cells and development.
[27] Thomas Ritter,et al. Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[28] Rocco,et al. Enabling Technologies for Cell-Based Clinical Translation Freshly Thawed and Continuously Cultured Human Bone Marrow-Derived Mesenchymal Stromal Cells Comparably Ameliorate Allergic Airways Inflammation in Immunocompetent Mice , 2015 .
[29] M. Hoogduijn,et al. Efficacy of immunotherapy with mesenchymal stem cells in man: a systematic review , 2015, Expert review of clinical immunology.
[30] Jane Ru Choi,et al. Phenotypic and Functional Characterization of Long-Term Cryopreserved Human Adipose-derived Stem Cells , 2015, Scientific Reports.
[31] Guido Moll,et al. Engineering more efficient multipotent mesenchymal stromal (stem) cells for systemic delivery as cellular therapy , 2015 .
[32] P. Raman,et al. Genomic and functional comparison of mesenchymal stromal cells prepared using two isolation methods. , 2015, Cytotherapy.
[33] O. Ringdén,et al. Immunogenicity of decidual stromal cells in an epidermolysis bullosa patient and in allogeneic hematopoietic stem cell transplantation patients. , 2015, Stem cells and development.
[34] K. Hoffmann,et al. Cryopreservation does not alter main characteristics of Good Manufacturing Process-grade human multipotent mesenchymal stromal cells including immunomodulating potential and lack of malignant transformation. , 2015, Cytotherapy.
[35] Jacques Galipeau,et al. The challenge of defining mesenchymal stromal cell potency assays and their potential use as release criteria. , 2015, Cytotherapy.
[36] O. Ringdén,et al. Treatment of severe chronic graft-versus-host disease with decidual stromal cells and tracing with (111)indium radiolabeling. , 2015, Stem cells and development.
[37] A. Efimenko,et al. Autologous Stem Cell Therapy: How Aging and Chronic Diseases Affect Stem and Progenitor Cells , 2015, BioResearch open access.
[38] J. Baust,et al. Biobanking: The Future of Cell Preservation Strategies. , 2015, Advances in experimental medicine and biology.
[39] A. Hubel,et al. Clinical mesenchymal stromal cell products undergo functional changes in response to freezing. , 2015, Cytotherapy.
[40] R. Shelton,et al. The effects of cryopreservation on cells isolated from adipose, bone marrow and dental pulp tissues. , 2014, Cryobiology.
[41] D. De Fazio,et al. Frozen adipose-derived mesenchymal stem cells maintain high capability to grow and differentiate. , 2014, Cryobiology.
[42] O. Korsgren,et al. Preserved β-Cell Function in Type 1 Diabetes by Mesenchymal Stromal Cells , 2014, Diabetes.
[43] B. Nilsson,et al. Cryopreserved Mesenchymal Stromal Cells Display Impaired Immunomodulatory and Therapeutic Properties ? , 2022 .
[44] Stefanie Dimmeler,et al. Translational strategies and challenges in regenerative medicine , 2014, Nature Medicine.
[45] O. Ringdén. Placenta-derived decidual stromal cells – a novel therapy for graft-versus-host disease, haemorrhages and toxicity after allogeneic haematopoietic stem cell transplantation , 2014 .
[46] W. Lam,et al. Actin Cytoskeletal Disruption following Cryopreservation Alters the Biodistribution of Human Mesenchymal Stromal Cells In Vivo , 2014, Stem cell reports.
[47] G. Stacey,et al. Putting cells to sleep for future science , 2014, Nature Biotechnology.
[48] J. Karp,et al. Mesenchymal stem cells: immune evasive, not immune privileged , 2014, Nature Biotechnology.
[49] R. Puri,et al. MSC-based product characterization for clinical trials: an FDA perspective. , 2014, Cell stem cell.
[50] J. Kurtzberg,et al. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[51] M. Griffin,et al. Autologous and allogeneic mesenchymal stem cells in organ transplantation: what do we know about their safety and efficacy? , 2014, Current opinion in organ transplantation.
[52] O. Ringdén,et al. Stromal cells–are they really useful for GVHD? , 2014, Bone Marrow Transplantation.
[53] B. Nilsson,et al. Do ABO Blood Group Antigens Hamper the Therapeutic Efficacy of Mesenchymal Stromal Cells? , 2014, PloS one.
[54] Yufang Shi,et al. Immunobiology of mesenchymal stem cells , 2013, Cell Death and Differentiation.
[55] M. Hoogduijn,et al. Morphology and size of stem cells from mouse and whale: observational study , 2013, BMJ.
[56] K. Schmidt-Bleek,et al. In serum veritas—in serum sanitas? Cell non-autonomous aging compromises differentiation and survival of mesenchymal stromal cells via the oxidative stress pathway , 2013, Cell Death and Disease.
[57] F. Locatelli,et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid‐refractory, grade III–IV acute graft‐versus‐host disease , 2013, British journal of haematology.
[58] H. Klüter,et al. Functional and differential proteomic analyses to identify platelet derived factors affecting ex vivo expansion of mesenchymal stromal cells , 2013, BMC Cell Biology.
[59] W. Fibbe,et al. Mesenchymal stromal cells: sensors and switchers of inflammation. , 2013, Cell stem cell.
[60] T. Ritter,et al. Concise review: Adult mesenchymal stromal cell therapy for inflammatory diseases: How well are we joining the dots? , 2013, Stem cells.
[61] D. Mougiakakos,et al. Alterations in the Cellular Immune Compartment of Patients Treated with Third‐Party Mesenchymal Stromal Cells Following Allogeneic Hematopoietic Stem Cell Transplantation , 2013, Stem cells.
[62] W. Weimar,et al. Mesenchymal stem cells induce an inflammatory response after intravenous infusion. , 2013, Stem cells and development.
[63] J. Galipeau. Concerns arising from MSC retrieval from cryostorage and effect on immune suppressive function and pharmaceutical usage in clinical trials , 2013 .
[64] O. Lindvall,et al. Regulation of stem cell therapies under attack in Europe: for whom the bell tolls , 2013, The EMBO journal.
[65] H. Reichenspurner,et al. Immunological properties of extraembryonic human mesenchymal stromal cells derived from gestational tissue. , 2013, Stem cells and development.
[66] Preeti Chhabra,et al. Stem Cell Therapy to Cure Type 1 Diabetes: From Hype to Hope , 2013, Stem cells translational medicine.
[67] Navrag B. Singh,et al. Terminally Differentiated CD8+ T Cells Negatively Affect Bone Regeneration in Humans , 2013, Science Translational Medicine.
[68] E. Horwitz. Advancing Regenerative Medicine the Translational Way , 2013, Science Translational Medicine.
[69] N. Fisk,et al. Mesenchymal stem cells for systemic therapy: shotgun approach or magic bullets? , 2013, BioEssays : news and reviews in molecular, cellular and developmental biology.
[70] O. Ringdén,et al. Fetal Membrane Cells for Treatment of Steroid‐Refractory Acute Graft‐Versus‐Host Disease , 2013, Stem cells.
[71] A. Thiel,et al. Concerted regulation of CD34 and CD105 accompanies mesenchymal stromal cell derivation from human adventitial stromal cell. , 2013, Stem cells and development.
[72] R. Henschler,et al. Cultivation in human serum reduces adipose tissue-derived mesenchymal stromal cell adhesion to laminin and endothelium and reduces capillary entrapment. , 2013, Stem cells and development.
[73] T. Okano,et al. Tissue factor triggers procoagulation in transplanted mesenchymal stem cells leading to thromboembolism. , 2013, Biochemical and biophysical research communications.
[74] L. Bouzas,et al. Stability of human mesenchymal stem cells during in vitro culture: considerations for cell therapy , 2013, Cell proliferation.
[75] G. Gross,et al. Stem Cell-Dependent Therapies: Mesenchymal Stem Cells in Chronic Inflammatory Disorders , 2013 .
[76] E. Colletti,et al. Mesenchymal Stem Cells Engineered to Inhibit Complement-Mediated Damage , 2012, PloS one.
[77] Jacques Galipeau,et al. The mesenchymal stromal cells dilemma--does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? , 2013, Cytotherapy.
[78] R. Henschler,et al. Fate of intravenously injected mesenchymal stem cells and significance for clinical application. , 2013, Advances in biochemical engineering/biotechnology.
[79] D. Kaufman,et al. Potential role of mesenchymal stromal cells in pancreatic islet transplantation. , 2013, Transplantation reviews.
[80] Xu Cao,et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine , 2013, Nature Medicine.
[81] S. Dow,et al. Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: results of three sequential pilot studies , 2013, Stem Cell Research & Therapy.
[82] U. Demirci,et al. Integrating nanoscale technologies with cryogenics: a step towards improved biopreservation. , 2012, Nanomedicine.
[83] F. Lin,et al. Mesenchymal stem cells are injured by complement after their contact with serum. , 2012, Blood.
[84] A. Das,et al. Comparative cellular and molecular analyses of pooled bone marrow multipotent mesenchymal stromal cells during continuous passaging and after successive cryopreservation , 2012, Journal of cellular biochemistry.
[85] E. Geissler,et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion , 2012, Front. Immun..
[86] C. Hermans,et al. Bivalirudin in Combination with Heparin to Control Mesenchymal Cell Procoagulant Activity , 2012, PloS one.
[87] O. Ringdén,et al. Analysis of Tissues Following Mesenchymal Stromal Cell Therapy in Humans Indicates Limited Long‐Term Engraftment and No Ectopic Tissue Formation , 2012, Stem cells.
[88] B. Nilsson,et al. Are Therapeutic Human Mesenchymal Stromal Cells Compatible with Human Blood? , 2012, Stem cells.
[89] M. Flowers,et al. Secondary treatment of acute graft-versus-host disease: a critical review. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[90] O. Lee,et al. Multiple Intravenous Transplantations of Mesenchymal Stem Cells Effectively Restore Long-Term Blood Glucose Homeostasis by Hepatic Engraftment and β-Cell Differentiation in Streptozocin-Induced Diabetic Mice , 2012, Cell transplantation.
[91] T. Redmer,et al. Replicative aging and differentiation potential of human adipose tissue-derived mesenchymal stromal cells expanded in pooled human or fetal bovine serum. , 2012, Cytotherapy.
[92] D. Mougiakakos,et al. Multipotent mesenchymal stromal cells and the innate immune system , 2012, Nature Reviews Immunology.
[93] B. Sander,et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[94] C. V. van Blitterswijk,et al. Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements. , 2012, Tissue engineering. Part B, Reviews.
[95] N. Kaji,et al. Monitoring transplanted adipose tissue-derived stem cells combined with heparin in the liver by fluorescence imaging using quantum dots. , 2012, Biomaterials.
[96] B. Grinblat,et al. Evaluation of bone marrow-derived mesenchymal stem cells after cryopreservation and hypothermic storage in clinically safe medium. , 2012, Tissue engineering. Part C, Methods.
[97] R. Romieu-Mourez,et al. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing , 2011, Cytotherapy.
[98] B. Nilsson,et al. Control of instant blood-mediated inflammatory reaction to improve islets of Langerhans engraftment , 2011, Current opinion in organ transplantation.
[99] W. Weimar,et al. Human Mesenchymal Stem Cells Are Susceptible to Lysis by CD8+ T Cells and NK Cells , 2011, Cell transplantation.
[100] M. Krampera,et al. Mesenchymal stromal cell ‘licensing’: a multistep process , 2011, Leukemia.
[101] O. Ringdén,et al. Pooled MSCs for treatment of severe hemorrhage , 2011, Bone Marrow Transplantation.
[102] E. Andreu,et al. Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial , 2011, Haematologica.
[103] John D Lambris,et al. Mesenchymal Stromal Cells Engage Complement and Complement Receptor Bearing Innate Effector Cells to Modulate Immune Responses , 2011, PloS one.
[104] Yu-Hsiang Chang,et al. Effective Treatment of Severe Steroid-Resistant Acute Graft-Versus-Host Disease With Umbilical Cord-Derived Mesenchymal Stem Cells , 2011, Transplantation.
[105] H. Northoff,et al. Expression of blood group genes by mesenchymal stem cells , 2011, British journal of haematology.
[106] A. Caplan,et al. Mesenchymal stem cells: mechanisms of inflammation. , 2011, Annual review of pathology.
[107] P. Bugert,et al. Altered gene expression in human adipose stem cells cultured with fetal bovine serum compared to human supplements. , 2010, Tissue engineering. Part A.
[108] Jakub Tolar,et al. Concise Review: Hitting the Right Spot with Mesenchymal Stromal Cells , 2010, Stem cells.
[109] J. Karp,et al. Mesenchymal stem cell therapy: Two steps forward, one step back. , 2010, Trends in Molecular Medicine.
[110] Carmen Koch,et al. How to track cellular aging of mesenchymal stromal cells? , 2010, Aging.
[111] E. Seifried,et al. Suspension medium influences interaction of mesenchymal stromal cells with endothelium and pulmonary toxicity after transplantation in mice. , 2010, Cytotherapy.
[112] R. Herrmann,et al. Prochymal Improves Response Rates In Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-GVHD) Involving The Liver And Gut: Results Of A Randomized, Placebo-Controlled, Multicenter Phase III Trial In GVHD , 2010 .
[113] John D Lambris,et al. Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition? , 2010, Trends in immunology.
[114] H. Ohgushi,et al. Single intra-arterial injection of mesenchymal stromal cells for treatment of steroid-refractory acute graft-versus-host disease: a pilot study. , 2010, Cytotherapy.
[115] F. Locatelli,et al. Mesenchymal Stromal Cells , 2009, Annals of the New York Academy of Sciences.
[116] D. Strunk,et al. Human Alternatives to Fetal Bovine Serum for the Expansion of Mesenchymal Stromal Cells from Bone Marrow , 2009, Stem cells.
[117] S. Savitz,et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. , 2009, Stem cells and development.
[118] Jeffrey M Karp,et al. Mesenchymal stem cell homing: the devil is in the details. , 2009, Cell stem cell.
[119] S. Totey,et al. Effect of holding time, temperature and different parenteral solutions on viability and functionality of adult bone marrow‐derived mesenchymal stem cells before transplantation , 2008, Journal of tissue engineering and regenerative medicine.
[120] A. Uccelli,et al. Mesenchymal stem cells in health and disease , 2008, Nature Reviews Immunology.
[121] Yilin Cao,et al. Evaluation of the viability and osteogenic differentiation of cryopreserved human adipose-derived stem cells. , 2008, Cryobiology.
[122] S. Dimmeler,et al. Aging and disease as modifiers of efficacy of cell therapy. , 2008, Circulation research.
[123] F. Ezquer,et al. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[124] G. Dini,et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study , 2008, The Lancet.
[125] E. Jones,et al. Age-related changes in human bone marrow-derived mesenchymal stem cells: Consequences for cell therapies , 2008, Mechanisms of Ageing and Development.
[126] R. Zhao,et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. , 2008, Cell Stem Cell.
[127] I. Koshima,et al. Preserved Proliferative Capacity and Multipotency of Human Adipose-Derived Stem Cells after Long-Term Cryopreservation , 2008, Plastic and reconstructive surgery.
[128] Toshio Miki,et al. Concise Review: Isolation and Characterization of Cells from Human Term Placenta: Outcome of the First International Workshop on Placenta Derived Stem Cells , 2008, Stem cells.
[129] E. Gócza,et al. Mesenchymal Stem Cells Cooperate with Bone Marrow Cells in Therapy of Diabetes , 2008, Stem cells.
[130] O. Ringdén,et al. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients , 2007, Haematologica.
[131] Q. Han,et al. Using human adipose tissue-derived mesenchymal stem cells as salvage therapy for hepatic graft-versus-host disease resembling acute hepatitis. , 2007, Transplantation proceedings.
[132] P. Quesenberry,et al. Cryopreservation of hematopoietic stem cells , 2007, American journal of hematology.
[133] H. Klüter,et al. Human AB Serum and Thrombin‐Activated Platelet‐Rich Plasma Are Suitable Alternatives to Fetal Calf Serum for the Expansion of Mesenchymal Stem Cells from Adipose Tissue , 2007, Stem cells.
[134] R. Robbins,et al. Stem cell transplantation: the lung barrier. , 2007, Transplantation proceedings.
[135] J. Laine,et al. N‐Glycolylneuraminic Acid Xenoantigen Contamination of Human Embryonic and Mesenchymal Stem Cells Is Substantially Reversible , 2007, Stem cells.
[136] Meijing Wang,et al. HIGH PASSAGE NUMBER OF STEM CELLS ADVERSELY AFFECTS STEM CELL ACTIVATION AND MYOCARDIAL PROTECTION , 2006, Shock.
[137] Darwin J. Prockop,et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice , 2006, Proceedings of the National Academy of Sciences.
[138] Hanns-Ulrich Marschall,et al. Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease , 2006, Transplantation.
[139] Hermann Eichler,et al. Comparative Analysis of Mesenchymal Stem Cells from Bone Marrow, Umbilical Cord Blood, or Adipose Tissue , 2006, Stem cells.
[140] Moustapha Hassan,et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.
[141] Shu-Ching Hsu,et al. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[142] A. Flake,et al. Mesenchymal stem cells: paradoxes of passaging. , 2004, Experimental hematology.
[143] L. Muul,et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[144] A. Caplan,et al. The Dynamic in vivo Distribution of Bone Marrow-Derived Mesenchymal Stem Cells after Infusion , 2001, Cells Tissues Organs.
[145] E. Ryan,et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. , 2000, The New England journal of medicine.
[146] M. Mastrogiacomo,et al. Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: Implications for their use in cell therapy. , 2000, Experimental hematology.
[147] G. Elgue,et al. Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? , 1999, Diabetes.
[148] S. Bruder,et al. Growth kinetics, self‐renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation , 1997, Journal of cellular biochemistry.
[149] A I Caplan,et al. The mesengenic process. , 1994, Clinics in plastic surgery.